Areas of interest (AOI) & competitive research grants
We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.
| Therapeutic Area and / or Compound | AOIs Posted on BMS.com | Pre-Concept Submission Period | |
| Start Date | End date | ||
| Cardiovascular - Mavacamten | 1/16/2026 | 2/6/2026 | 2/19/2026 |
Mavacamten 2026 ISR RFP Cycle 1 AOIs
Cardiovascular - Mavacamten
CAMZYOS impact on long-term disease
In Scope:
- Impact of mavacamten on morbidity and quality of life
- Association between indicators of remodeling and clinical outcomes
- Impact on patients with earlier disease (less symptomatic, milder phenotype)
- Impact of mavacamten on disease or long-term outcome, ie. cardiac structure, underline diseases, risk factors
- Impact on patients with clinically significant comorbidities (e.g., pulmonary hypertension, diastolic dysfunction, renal impairment) on their oHCM disease
Out of Scope:
- Head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; Myosin genotyping
- AI-based tools, algorithms, or technologies for diagnosis or patient identification in obstructive HCM (e.g., Viz-AI, etc.).
- Repeat of BMS clinical trial data
- Post-hoc analysis and/or reanalysis of BMS clinical data
- Studies with biomarker data as primary endpoint
- Camzyos use in off label populations (LVEF < 50%, NYHA I and IV, nHCM, <18yo)
- Role of mavacamten in competitive sports and athletes with oHCM (e.g., amateur or professional participating in official sports competition)
Implementation of best practices
In Scope:
- Decision-making support to include patient-preference/patient reported outcomes
- Approaches to workflow optimization, care coordination, or management processes (quality–improvement studies, improvement of diagnosis)
- Impact on real world clinical use (e.g., with or without background meds, transition of care, etc.)
Out of Scope:
- Head-to-head comparisons between CAMZYOS and other treatments; pre-clinical studies, CYP2C19 genotyping; Myosin genotyping
- AI-based tools, algorithms, or technologies for diagnosis or patient identification in obstructive HCM (e.g., Viz-AI, etc.).
- Repeat of BMS clinical trial data
- Post-hoc analysis and/or reanalysis of BMS clinical data
- Studies with biomarker data as primary endpoint
- Camzyos use in off label populations (LVEF < 50%, NYHA I and IV, nHCM, <18yo)
- Role of mavacamten in competitive sports and athletes with oHCM (e.g., amateur or professional participating in official sports competition)
Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.
- If you are a potential investigator who is interested in seeking support to conduct independent research involving Nivolumab in Japan, Taiwan, or Korea, click here
- If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
- If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
- If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here